Context Therapeutics Inc.
CNTX
$1.52
-$0.19-11.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.69% | 9.60% | 0.65% | 13.13% | 11.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.99% | 220.26% | -43.26% | 215.96% | 44.61% |
| Operating Income | -68.99% | -220.26% | 43.26% | -215.96% | -44.61% |
| Income Before Tax | -89.64% | -289.65% | 44.48% | -291.55% | -24.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -89.64% | -289.65% | 44.48% | -291.55% | -24.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -89.64% | -289.65% | 44.48% | -291.55% | -24.80% |
| EBIT | -68.99% | -220.26% | 43.26% | -215.96% | -44.61% |
| EBITDA | -69.03% | -220.39% | 43.28% | -216.08% | -44.60% |
| EPS Basic | -89.60% | -235.29% | 53.07% | -126.10% | 79.06% |
| Normalized Basic EPS | -89.37% | -235.29% | 53.10% | -126.56% | 79.04% |
| EPS Diluted | -82.40% | -235.29% | 53.07% | -126.10% | 78.23% |
| Normalized Diluted EPS | -89.37% | -235.29% | 53.10% | -126.56% | 79.04% |
| Average Basic Shares Outstanding | 0.00% | 16.18% | 18.27% | 73.20% | 496.18% |
| Average Diluted Shares Outstanding | 0.00% | 16.18% | 18.27% | 73.20% | 496.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |